Consensus Dr. Reddy's Laboratories Limited NSE India S.E.

Equities

DRREDDY

INE089A01023

Market Closed - NSE India S.E. Other stock markets 05:17:53 21/06/2024 pm IST			5-day change	1st Jan Change
6,011 ^INR	+0.68%		-1.21%	+3.68%

21/06	Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	MT
18/06	Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT

Evolution of the average Target Price on Dr. Reddy's Laboratories Limited

Price target over the last 5 years

History of analyst recommendation changes

dd759dca359a3.zIcJHI1vJW1DibhMML4NFk5doKIsK75DMc9eLvkSQ7M.mup6VOEqVkAxvf0nSuw0IhoHw9JWe8x2Vb8vWZ17L4eDz25F_SRLJgfe4Q~65c681c68821b823c96a812a5d77d817

Analyst Recommendations on Dr. Reddy's Laboratories Limited

Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR5,010 From INR5,040, Keeps at Underperform	08/05	MT
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $80 From $75, Keeps Overweight Rating	29/01	MT
Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR6,250 From INR6,330, Keeps at Buy	30/23/30	MT
Jefferies Adjusts Dr. Reddy Laboratories’ to INR6,300 From INR5,600, Keeps at Buy	27/23/27	MT
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $70 From $67, Maintains Overweight Rating	01/23/01	MT
Nomura Adjusts Dr Reddy's Laboratories' Price Target to INR5,161 From INR5,552, Keeps at Buy	30/23/30	MT
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $66 From $69, Reiterates Overweight Rating	25/22/25	MT
Barclays Adjusts Dr. Reddy's Laboratories' Price Target to $69 from $68, Maintains Overweight Rating	12/22/12	MT
Barclays Lowers Dr. Reddy's Laboratories' Price Target to $68 From $70, Maintains Overweight Rating	25/22/25	MT
Nomura Adjusts Dr. Reddy's Laboratories’ Price Target to 5,552 Indian Rupees From 5,856 Indian Rupees, Keeps at Buy	31/22/31	MT
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $80 From $78, Maintains Overweight Rating	01/21/01	MT
Nomura Adjusts Dr Reddy's Laboratories' Price Target to 5,856 Indian Rupees From 5,619 Indian Rupees, Keeps at Buy	01/21/01	MT
DR REDDY LABORATORIES : Nomura Adjusts Dr. Reddy's Laboratories' Price Target to 5,619 Indian Rupees From 6,145 Indian Rupees, Keeps at Buy	29/21/29	MT
DR REDDY LABORATORIES' : Price Target From Nomura Raised to INR6,145 From INR5,065, Buy Rating Maintained	18/21/18	MT
DR REDDY LABORATORIES : Nomura Adjusts Dr. Reddy's Laboratories' Price Target to 6,145 Indian Rupees From 5,065 Indian Rupees, Keeps at Buy	18/21/18	MT
Sub: Intimation for withdrawal of Credit Rating (Form 6-K)	12/21/12	PU
Dr Reddy Laboratories : India Ratings & Research Withdraws A1+ Rating on Dr. Reddy's Laboratories' Commercial Paper	10/21/10	MT
Wockhardt : CARE Ratings Gives BBB- Rating on Wockhardt's Proposed Non-Convertible Bonds; Outlook Stable	07/21/07	MT
-ANALYST ACTIONS : Nomura Upgrades Dr. Reddy's Laboratories to Buy From Neutral, Cuts Price Target to INR5,065 From INR5,165	22/21/22	MT
DR REDDY LABORATORIES : Nomura Upgrades Dr Reddy's Laboratories to Buy From Neutral, Adjusts Price Target to 5,065 Indian Rupees From 5,165 Indian Rupees	22/21/22	MT
Axis Bank : Indian shares close at record highs; RBI rate decision awaited	04/21/04	RE
DR REDDY LABORATORIES : Barclays Upgrades Dr. Reddy's Laboratories to Overweight From Equal-Weight, Adjusts Price Target to $70 From $56	02/21/02	MT
DR REDDY LABORATORIES : Nomura Downgrades Dr Reddy's Laboratories to Neutral From Buy, Adjusts Price Target to 5,165 Indian Rupees From 6,066 Indian Rupees	01/21/01	MT
Dr Reddy Laboratories : Intimation of Credit Rating – May 01, 2020	05/20/05	PU
Dr. Reddy's Laboratories Limited Announces Consolidated Earnings Results for the Second Quarter and Half Year Ended September 30, 2018; Provides Earnings Guidance for the Second Half of Fiscal 2019 and Effective Tax Rate Guidance for the Full Year of Fiscal 2019	26/18/26	CI